Noticias de Eulerpool Cyteir Therapeutics

Cyteir Therapeutics Eulerpool-AFX

Cyteir Therapeutics Noticias de Acciones

Cyteir Therapeutics es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Cyteir Therapeutics.

• 7 de marzo ·

  Yahoo
  Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
• 7 de marzo ·

  Thefly.com
  Cyteir Therapeutics announces timeline for voluntarily delisting from Nasdaq
• 20 de febrero ·

  Business Wire
  Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
• 5 de enero ·

  Thefly.com
  Cyteir Therapeutics downgraded to Underperform at BofA, coverage terminated
• 1 de noviembre ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 20.00% to 3.06
• 12 de octubre ·

  Yahoo
  Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
• 12 de octubre ·

  Thefly.com
  Cyteir: Cohort of CYT-0851 in combo for ovarian cancer well tolerated
• 18 de septiembre ·

  SeekingAlpha
  Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
• 11 de julio ·

  Fintel
  Fmr Now Owns 2.33% of Cyteir Therapeutics (CYT)
• 6 de julio ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 7.14% to 2.55